Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | CES2 | O00748 | 2/20 | 0.51 |
| ▸ | CES1 | P23141 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | JAK2 | O60674 | 1/20 | 0.51 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.51 |
| ▸ | TACR1 | P25103 | 1/20 | 0.50 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18240156 | 0.98 | NPC1 (0.54) | NPC1RAB9ANPSR1KMT2AALDH1A1 | |
| SCHEMBL18240146 | 0.98 | NPC1 (0.54) | NPC1RAB9ANPSR1KMT2AALDH1A1 | |
| SCHEMBL28533625 | 0.98 | NPC1 (0.54) | NPC1RAB9ANPSR1KMT2AALDH1A1 | |
| SCHEMBL7643097 | 0.98 | NPC1 (0.54) | NPC1RAB9ANPSR1KMT2AALDH1A1 | |
| SCHEMBL12472589 | 0.98 | NPC1 (0.54) | NPC1RAB9ANPSR1KMT2AALDH1A1 | |
| SCHEMBL7978813 | 0.94 | ALDH1A1 (0.55) | NPC1RAB9ANPSR1KMT2AALDH1A1 | |
| SCHEMBL8010837 | 0.91 | NPC1 (0.45) | NPC1RAB9ANPSR1KMT2AALDH1A1 | |
| SCHEMBL8001875 | 0.91 | NPC1 (0.45) | NPC1RAB9ANPSR1KMT2AALDH1A1 | |
| SCHEMBL6673813 | 0.90 | NPSR1 (0.63) | NPC1RAB9ANPSR1KMT2AALDH1A1 | |
| SCHEMBL18240148 | 0.89 | SOAT2 (0.58) | NPSR1KMT2AALDH1A1POLBEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023247697-A1 | NOVEL IRON-BASED COMPOUNDS, PROCESSES FOR THE PREPARATION THEREOF, AND USE THEREOF AS CATALYSTS | Universite Paris-Saclay (FR) | 2023-12-28 | — | — | WO | disclosed |
| US-20230225973-A1 | MULTI-LAYERED MEDICAMENT FOR INHALATION | MYLAN PHARMA UK LIMITED (GB) | 2023-07-20 | — | — | US | disclosed |
| CN-114478609-B | Method for using thiophenol photocatalyst in defluorination alkylation or defluorination protonation reaction | 中国科学技术大学 | 2023-06-16 | — | — | CN | disclosed |
| EP-4171524-A1 | MULTI-LAYERED MEDICAMENT FOR INHALATION | Mylan Pharma UK Limited (GB) | 2023-05-03 | — | — | EP | disclosed |
| CN-114478609-A | Method for applying thiophenol photocatalyst to defluorination alkylation or defluorination protonation reaction | 中国科学技术大学 | 2022-05-13 | — | — | CN | disclosed |
| WO-2021260437-A1 | MULTI-LAYERED MEDICAMENT FOR INHALATION | MYLAN PHARMA UK LIMITED (GB) | 2021-12-30 | — | — | WO | disclosed |
| US-8268881-B2 | Carboxamide derivatives as muscarinic receptor antagonists | PFIZER LIMITED (GB) | 2012-09-18 | — | — | US | disclosed |
| US-7772223-B2 | 5-Methyl-5-(3-phenoxyazetidin-1-yl)-2,2-diphenylhexanamide, used for the treatment of respiratory system disorders such as asthma, chronic obstructive pulmonary disease, adult respiratory distress syndrome, bronchitis and emphysema | PFIZER INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-20100029720-A1 | Carboxamide Derivatives As Muscarinic Receptor Antagonists | GLOSSOP PAUL ALAN | 2010-02-04 | — | — | US | disclosed |
| US-20070105831-A1 | Carboxamide derivatives as muscarinic receptor antagonists | PFIZER LIMITED | 2007-05-10 | — | — | US | disclosed |
| US-6235730-B1 | ANTICHOLESTEROL AGENT, ANTILIPEMIC AGENT | JAPAN TOBACCO, INC. (JP) | 2001-05-22 | — | — | US | disclosed |
| EP-0970954-A1 | 3-PIPERIDYL-4-OXOQUINAZOLINE DERIVATIVES AND MEDICINCAL COMPOSITIONS CONTAINING THE SAME | JAPAN TOBACCO INC. (JP) | 2000-01-12 | — | — | EP | disclosed |
| US-5298627-A | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis | WARNER-LAMBERT COMPANY (US) | 1994-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105831-A1 | Carboxamide derivatives as muscarinic receptor antagonists | CHRM3, CHRM5, CHRM2 | NPC1 2819/4885RAB9A 2629/4885NPSR1 174/4885 |
| US-20230225973-A1 | MULTI-LAYERED MEDICAMENT FOR INHALATION | NDUFB5, NDUFB7, NDUFB8 | NPC1 872/4885RAB9A 4489/4885NPSR1 1567/4885 |
| US-20100029720-A1 | Carboxamide Derivatives As Muscarinic Receptor Antagonists | CHRM3, CHRM5, CHRM2 | NPC1 2819/4885RAB9A 2629/4885NPSR1 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.